文献速递系统性红斑狼疮

模块化转录组分析识别血液中性粒细胞特征作为狼疮肾炎的候选生物标志物

Modular transcriptional repertoire analyses identify a blood neutrophil signature as a candidate biomarker for lupus nephritis.
PubMed 文献 · Rheumatology (Oxford) · 2017-01-01

该研究通过血液样本的模块化转录组分析,发现中性粒细胞特征(模块M5.15上调)在65%的SLE患者中存在,且与狼疮肾炎(LN)强烈相关;M5.15活性在LN中高于肾外 flares(88% vs 17%),与LN严重程度、增殖性及治疗反应相关,并与LN的既往、当前或未来 flares 相关。结论提示模块化中性粒细胞特征可能作为分层LN风险和监测治疗反应的生物标志物。

要点

  • 模块M5.15中性粒细胞特征在65%的SLE患者中上调,与LN强烈相关。
  • M5.15活性在LN中高于肾外 flares(88% vs 17%),且与LN严重程度及增殖性相关。
  • M5.15活化与LN的既往、当前或未来 flares 相关,可能用于风险分层和疗效监测。

核心结论

  • 模块化中性粒细胞特征可能作为分层LN风险和监测治疗反应的生物标志物。

研究设计与样本

  • 研究使用活检证实的LN、肾外SLE flares或静息SLE患者的血液样本,并纳入健康对照、肾小球疾病或细菌性脓毒症对照患者。
  • 通过微阵列数据的模块化转录组分析评估血液转录特征与LN的关联,并用PCR确认。

主要发现

  • 模块化中性粒细胞特征(模块M5.15上调)存在于65%的SLE患者中,并与LN强烈相关。
  • M5.15活性在LN中强于肾外 flares(88% vs 17%)。
  • M5.15与IFN模块、SLEDAI或抗dsDNA抗体不相关,但与糖皮质激素剂量中度相关。
  • M5.15活性与LN严重程度相关,增殖性时更强,治疗应答患者中下降。
  • 在静息患者中,有LN既往史者M5.15活性更高(50% vs 8%)。

关键数值与推荐

  • 模块M5.15上调在65%的SLE患者中检出。
  • M5.15活性在LN中为88%,在肾外 flares 中为17%。
  • 静息患者中有LN既往史者M5.15活性为50%,无LN既往史者为8%。

临床怎么用

  • 模块化中性粒细胞特征可能用于分层LN风险。
  • 该特征可能用于监测LN对治疗的反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: LN is a severe complication of SLE. Non-invasive biomarkers are needed for identifying patients at risk of a renal flare, for differentiating proliferative from non-proliferative forms and for assessing prognoses for LN. METHODS: We assessed the link between blood transcriptional signatures and LN using blood samples from patients with biopsy-proven LN, extra-renal SLE flares or quiescent SLE. Healthy controls, and control patients with glomerular diseases or bacterial sepsis were included. Modular repertoire analyses from microarray data were confirmed by PCR. RESULTS: A modular neutrophil signature (upregulation of module M5.15) was present in 65% of SLE patients and was strongly associated with LN. M5.15 activity was stronger in LN than in extra-renal flares (88 vs 17%). M5.15 was neither correlated to IFN modules, nor to SLEDAI or anti-dsDNA antibodies, but moderately to CS dose. M5.15 activity was associated with severity of LN, was stronger when proliferative, and decreased in patients responding to treatment. M5.15 activation was not caused by higher CS dose because it correlated only moderately to neutrophil count and was also observed among quiescent patients. Among quiescent patients, those with a past history of LN had higher M5.15 activity (50 vs 8%). M5.15 activation was present in patients with bacterial sepsis or ANCA-associated vasculitis, but not in patients with other glomerular diseases. Overall, M5.15 activation was associated with past, present or future flares of LN. CONCLUSION: Modular neutrophil signature could be a biomarker for stratifying LN risk and for monitoring its response to treatment. TRIAL REGISTRATION: ClinicalTrials.gov, http://clinicaltrials.gov , NCT00920114.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Jourde-Chiche N, Whalen E, Gondouin B, et al. Modular transcriptional repertoire analyses identify a blood neutrophil signature as a candidate biomarker for lupus nephritis. Rheumatology (Oxford). 2017. PMID: 28031441. doi:10.1093/rheumatology/kew439

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。